The State Administration of Ukraine on Medicinal Products has elaborated a draft of Law of Ukraine "On Amendments to Article 15 of the Law of Ukraine "On Medicinal Products "(hereinafter - the Law).
The draft is expected to expand the control function of the State Administration of Ukraine on Medicinal Products and to give its authorities the authority to terminate producing (manufacturing) and realization of medicinal products on the basis of act drawn up by the results of the conducting of the measure, which elicited the violation of the law. Only then, of the State Administration of Ukraine on Medicinal Products appeals on terms, set by CASP of Ukraine, to the administrative court for confirmation of reasonability for the economic entity to take such measures.
Recall that to date, this term is 15 days and will be calculated from the date of taking of appropriate responsive measures by authorities of the State Administration of Ukraine on Medicinal Products.
At that, the draft has more criticism than positive assessments. This draft is proposed to establish an opportunity not only to terminate the activity of pharmaceutical companies actually for a period of 15 days on the basis of the act of administrative authority, the State Administration of Ukraine on Medicinal Products, which does not correspond with the provisions of the existing Law of Ukraine "On framework of state control in the sphere of economic activity", moreover during this term representatives of pharmaceutical sector denied the possibility to appeal noted decision.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.